Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Neuropsychologic Assessments of Dupilumab-Treated Adolescents With Moderate-to-Severe Atopic Dermatitis

NCT05203380 is registered in ClinicalTrials.gov with Regeneron Pharmaceuticals as lead sponsor.

NCT NCT05203380
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05203380 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Neuropsychologic Assessments of Dupilumab-Treated Adolescents With Moderate-to-Severe Atopic Dermatitis
Lead sponsor
Regeneron Pharmaceuticals
Phase
Observational
Overall status
Completed
Start date
January 27, 2022
Completion date
March 10, 2023
Enrollment
45 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

moderate-to-severe atopic dermatitis